Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 10/20 | 0.72 |
| ▸ | CPA3 | P15088 | 3/20 | 0.72 |
| ▸ | CPB1 | P15086 | 1/20 | 0.72 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | MME | P08473 | 1/20 | 0.62 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.61 |
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266746 | 0.89 | CYP1A2 (0.59) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL5688996 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL1915564 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL393002 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL4664822 | 0.83 | CYP1A2 (1.00) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL3421012 | 0.82 | CPA1 (0.96) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL7286643 | 0.81 | CPA1 (0.70) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL7439697 | 0.81 | CYP1A2 (0.86) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL9622038 | 0.81 | CYP1A2 (0.86) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL22115491 | 0.81 | CYP1A2 (0.95) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167024-B1 | COOLING COMPOUNDS | GIVAUDAN SA (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-7959958-B2 | Cooling compounds | Givaudan, S.A. (CH) | 2011-06-14 | — | — | US | disclosed |
| EP-2167024-A2 | COOLING COMPOUNDS | Givaudan SA (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20080311232-A1 | Cooling Compounds | GIVAUDAN, SA (CH) | 2008-12-18 | — | — | US | disclosed |
| WO-2008151460-A2 | COOLING COMPOUNDS | GIVAUDAN SA (CH) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311232-A1 | Cooling Compounds | MAL2, NCOR2, NCOA2 | CPA1 3888/4885CPA3 2981/4885CPB1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.